S&P 500   4,349.93
DOW   34,168.09
QQQ   344.57
S&P 500   4,349.93
DOW   34,168.09
QQQ   344.57
S&P 500   4,349.93
DOW   34,168.09
QQQ   344.57
S&P 500   4,349.93
DOW   34,168.09
QQQ   344.57

Dechra Pharmaceuticals Share Forecast, Price & News

GBX 4,004
+36.00 (+0.91%)
(As of 01/27/2022 10:25 AM ET)
Today's Range
50-Day Range
52-Week Range
27,768 shs
Average Volume
289,727 shs
Market Capitalization
£4.34 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive DPH News and Ratings via Email

Sign-up to receive the latest news and ratings for Dechra Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Dechra Pharmaceuticals logo

About Dechra Pharmaceuticals

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians worldwide. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.


See More Headlines

Industry, Sector and Symbol

Drug Manufacturers - Major
Year Founded

Sales & Book Value

Annual Sales
£608 million
Cash Flow
GBX 97.71 per share
Book Value
GBX 584.90 per share


Pretax Margin




Free Float
Market Cap
£4.34 billion
Not Optionable

Company Calendar

Ex-Dividend for 11/19 Dividend
Dividend Payable
Next Earnings (Estimated)


Overall MarketRank

1.56 out of 5 stars

Analyst Opinion: 2.0Community Rank: 4.1Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Dechra Pharmaceuticals (LON:DPH) Frequently Asked Questions

Is Dechra Pharmaceuticals a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dechra Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Dechra Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DPH, but not buy additional shares or sell existing shares.
View analyst ratings for Dechra Pharmaceuticals
or view top-rated stocks.

How has Dechra Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Dechra Pharmaceuticals' stock was trading at GBX 2,472 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, DPH stock has increased by 62.0% and is now trading at GBX 4,004.
View which stocks have been most impacted by COVID-19

When is Dechra Pharmaceuticals' next earnings date?

Dechra Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, February 21st 2022.
View our earnings forecast for Dechra Pharmaceuticals

How often does Dechra Pharmaceuticals pay dividends? What is the dividend yield for Dechra Pharmaceuticals?

Dechra Pharmaceuticals announced a dividend on Monday, September 6th. Investors of record on Thursday, October 28th will be paid a dividend of GBX 29.39 per share on Friday, November 19th. This represents a yield of 0.63%. The ex-dividend date is Thursday, October 28th. This is a boost from Dechra Pharmaceuticals's previous dividend of GBX 11.11. The official announcement can be seen at this link.
View Dechra Pharmaceuticals' dividend history

Is Dechra Pharmaceuticals a good dividend stock?

Dechra Pharmaceuticals pays an annual dividend of GBX 0.35 per share and currently has a dividend yield of 1.01%. The dividend payout ratio of Dechra Pharmaceuticals is 0.69%. This payout ratio is at a healthy, sustainable level, below 75%.
View Dechra Pharmaceuticals' dividend history.

What price target have analysts set for DPH?

3 analysts have issued 12 month target prices for Dechra Pharmaceuticals' stock. Their forecasts range from GBX 3,960 to GBX 5,700. On average, they anticipate Dechra Pharmaceuticals' share price to reach GBX 4,986.67 in the next year. This suggests a possible upside of 24.5% from the stock's current price.
View analysts' price targets for Dechra Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Dechra Pharmaceuticals' key executives?

Dechra Pharmaceuticals' management team includes the following people:
  • Mr. Ian D. Page, CEO, MD & Exec. Director (Age 60, Pay $793k)
  • Mr. Paul Nicholas Sandland MAAT, FCCA, CFO & Exec. Director (Age 42, Pay $375.6k)
  • Dr. Anthony Gerard Griffin, MD of Dechra Veterinary Products for Europe & Exec. Director (Age 58, Pay $466k)
  • Dr. Susan Longhofer, Chief Scientific Officer (Age 63)
  • Ms. Katy Clough, Group HR Director
  • Mr. Mike Eldred, Pres of North America (Age 51)
  • Ms. Melanie Hall, Company Sec.

What other stocks do shareholders of Dechra Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dechra Pharmaceuticals investors own include 32Red (TTR), 1428686 (SGP.L) (SGP), JD Sports Fashion (JD), Ashtead Group (AHT), Cranswick (CWK), Drax Group (DRX), RPC Group (RPC), Robert Walters (RWA), SEB (SKP) and Barratt Developments (BDEV).

What is Dechra Pharmaceuticals' stock symbol?

Dechra Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "DPH."

How do I buy shares of Dechra Pharmaceuticals?

Shares of DPH and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Dechra Pharmaceuticals' stock price today?

One share of DPH stock can currently be purchased for approximately GBX 4,004.

How much money does Dechra Pharmaceuticals make?

Dechra Pharmaceuticals has a market capitalization of £4.34 billion and generates £608 million in revenue each year.

How many employees does Dechra Pharmaceuticals have?

Dechra Pharmaceuticals employs 1,889 workers across the globe.

What is Dechra Pharmaceuticals' official website?

The official website for Dechra Pharmaceuticals is www.dechra.com.

Where are Dechra Pharmaceuticals' headquarters?

How can I contact Dechra Pharmaceuticals?

Dechra Pharmaceuticals' mailing address is 24 Cheshire Business Park Cheshire Avenue, NORTHWICH, CW9 7UA, United Kingdom. The company can be reached via phone at +44-1606-814730.

This page was last updated on 1/27/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.